Abington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 16 / 16.9 / 94.6 / (54.0-153.6) / Male / 13 / 11.0 / 118.3 / (62.9-202.3)
Female / 3 / 6.3 / nc / (nc-nc) / Female / 10 / 8.9 / 112.9 / (54.1-207.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 7 / 3.4 / 204.3 / (81.9-421.0) / Male / 1 / 2.7 / nc / (nc-nc)
Female / 3 / 2.8 / nc / (nc-nc) / Female / 2 / 2.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.5 / nc / (nc-nc) / Male / 11 / 9.4 / 117.5 / (58.6-210.2)
Female / 61 / 62.4 / 97.7 / (74.7-125.5) / Female / 11 / 8.2 / 134.0 / (66.8-239.8)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 6.7 / 104.4 / (41.8-215.1)
Female / 4 / 2.7 / nc / (nc-nc) / Female / 2 / 3.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 21 / 22.8 / 92.0 / (56.9-140.7)
Female / 30 / 21.9 / 136.9 / (92.3-195.4) / Female / 9 / 6.3 / 142.7 / (65.1-271.0)
Esophagus / Pancreas
Male / 6 / 4.5 / 133.9 / (48.9-291.5) / Male / 1 / 5.2 / nc / (nc-nc)
Female / 2 / 1.2 / nc / (nc-nc) / Female / 7 / 5.4 / 129.0 / (51.7-265.8)
Hodgkin Lymphoma / Prostate
Male / 5 / 1.5 / 326.6 / (105.3-762.3) / Male / 49 / 64.4 / 76.0 / (56.3-100.5)
Female / 0 / 1.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 8 / 8.5 / 94.2 / (40.6-185.6) / Male / 7 / 4.0 / 176.0 / (70.5-362.7)
Female / 8 / 5.1 / 157.5 / (67.8-310.4) / Female / 1 / 2.4 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 2.7 / nc / (nc-nc) / Male / 2 / 2.5 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 5 / 5.9 / 84.1 / (27.1-196.2) / Male / 1 / 3.1 / nc / (nc-nc)
Female / 2 / 4.5 / nc / (nc-nc) / Female / 8 / 10.0 / 80.2 / (34.5-157.9)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 4.3 / 117.6 / (37.9-274.4)
Female / 2 / 1.5 / nc / (nc-nc) / Female / 12 / 13.9 / 86.5 / (44.7-151.2)
Lung and Bronchus / All Sites / Types
Male / 34 / 30.9 / 110.1 / (76.2-153.9) / Male / 219 / 228.2 / 96.0 / (83.7-109.6)
Female / 36 / 30.5 / 117.9 / (82.6-163.2) / Female / 231 / 218.3 / 105.8 / (92.6-120.4)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
10
Acton
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 11 / 16.4 / 66.9 / (33.4-119.7) / Male / 23 / 12.3 / 187.2 / (118.7-281.0)
Female / 5 / 5.8 / 85.8 / (27.6-200.2) / Female / 13 / 10.2 / 127.9 / (68.0-218.7)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 4.1 / nc / (nc-nc) / Male / 4 / 2.8 / nc / (nc-nc)
Female / 3 / 3.1 / nc / (nc-nc) / Female / 3 / 1.9 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.5 / nc / (nc-nc) / Male / 7 / 10.3 / 68.3 / (27.4-140.7)
Female / 94 / 71.9 / 130.7 / (105.7-160.0) / Female / 11 / 8.1 / 135.2 / (67.4-241.9)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 7.9 / 63.4 / (20.4-147.9)
Female / 1 / 3.4 / nc / (nc-nc) / Female / 2 / 3.3 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 24 / 23.7 / 101.2 / (64.8-150.6)
Female / 15 / 20.7 / 72.3 / (40.4-119.3) / Female / 11 / 6.9 / 159.6 / (79.6-285.6)
Esophagus / Pancreas
Male / 3 / 4.8 / nc / (nc-nc) / Male / 7 / 5.3 / 132.1 / (52.9-272.2)
Female / 0 / 1.1 / nc / (nc-nc) / Female / 7 / 5.0 / 140.5 / (56.3-289.4)
Hodgkin Lymphoma / Prostate
Male / 1 / 1.8 / nc / (nc-nc) / Male / 67 / 69.0 / 97.2 / (75.3-123.4)
Female / 0 / 1.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 9.6 / 62.5 / (22.8-136.1) / Male / 4 / 4.0 / nc / (nc-nc)
Female / 4 / 5.3 / nc / (nc-nc) / Female / 2 / 2.2 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 2.9 / nc / (nc-nc) / Male / 8 / 3.2 / 253.0 / (108.9-498.6)
Female / 1 / 0.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 6 / 6.3 / 95.0 / (34.7-206.8) / Male / 3 / 3.9 / nc / (nc-nc)
Female / 6 / 4.6 / 129.5 / (47.3-281.8) / Female / 12 / 12.7 / 94.1 / (48.6-164.5)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 4.9 / 101.4 / (32.7-236.6)
Female / 0 / 1.4 / nc / (nc-nc) / Female / 13 / 15.7 / 82.9 / (44.1-141.7)
Lung and Bronchus / All Sites / Types
Male / 15 / 31.2 / 48.1 / (26.9-79.3) / Male / 218 / 242.6 / 89.9 / (78.3-102.6)
Female / 21 / 29.2 / 71.9 / (44.5-110.0) / Female / 236 / 231.9 / 101.8 / (89.2-115.6)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
11
Acushnet
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 10 / 12.8 / 78.0 / (37.3-143.4) / Male / 6 / 8.0 / 74.7 / (27.3-162.5)
Female / 4 / 4.4 / nc / (nc-nc) / Female / 4 / 6.1 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 2.4 / nc / (nc-nc) / Male / 2 / 2.0 / nc / (nc-nc)
Female / 0 / 1.9 / nc / (nc-nc) / Female / 0 / 1.4 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 3 / 6.9 / nc / (nc-nc)
Female / 37 / 44.0 / 84.0 / (59.1-115.8) / Female / 4 / 5.7 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 4.9 / 101.8 / (32.8-237.6)
Female / 0 / 1.8 / nc / (nc-nc) / Female / 1 / 2.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 20 / 17.1 / 117.0 / (71.5-180.7)
Female / 21 / 15.2 / 138.2 / (85.5-211.3) / Female / 4 / 4.4 / nc / (nc-nc)
Esophagus / Pancreas
Male / 3 / 3.4 / nc / (nc-nc) / Male / 3 / 3.9 / nc / (nc-nc)
Female / 1 / 0.8 / nc / (nc-nc) / Female / 3 / 3.8 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 1.0 / nc / (nc-nc) / Male / 64 / 48.4 / 132.2 / (101.8-168.8)
Female / 0 / 0.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 7 / 6.3 / 111.0 / (44.5-228.7) / Male / 7 / 3.0 / 235.3 / (94.3-484.8)
Female / 5 / 3.6 / 138.5 / (44.6-323.2) / Female / 0 / 1.7 / nc / (nc-nc)
Larynx / Testis
Male / 6 / 2.0 / 298.6 / (109.0-650.0) / Male / 0 / 1.6 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 4.3 / nc / (nc-nc) / Male / 4 / 2.2 / nc / (nc-nc)
Female / 3 / 3.1 / nc / (nc-nc) / Female / 5 / 6.8 / 73.7 / (23.8-172.0)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 3.2 / 157.5 / (50.8-367.6)
Female / 0 / 1.0 / nc / (nc-nc) / Female / 6 / 9.9 / 60.8 / (22.2-132.2)
Lung and Bronchus / All Sites / Types
Male / 28 / 23.6 / 118.7 / (78.8-171.5) / Male / 191 / 170.2 / 112.2 / (96.9-129.3)
Female / 16 / 21.9 / 72.9 / (41.7-118.4) / Female / 127 / 153.1 / 82.9 / (69.1-98.7)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
12
Adams
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 15 / 12.8 / 117.5 / (65.7-193.7) / Male / 4 / 7.2 / nc / (nc-nc)
Female / 5 / 5.0 / 99.2 / (32.0-231.6) / Female / 1 / 5.7 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 2.1 / nc / (nc-nc) / Male / 1 / 1.9 / nc / (nc-nc)
Female / 3 / 1.8 / nc / (nc-nc) / Female / 1 / 1.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 6 / 6.3 / 94.6 / (34.5-205.8)
Female / 41 / 41.7 / 98.4 / (70.6-133.4) / Female / 7 / 6.2 / 112.7 / (45.2-232.3)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 4.2 / nc / (nc-nc)
Female / 0 / 1.5 / nc / (nc-nc) / Female / 1 / 2.2 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 25 / 16.3 / 153.7 / (99.5-227.0)
Female / 25 / 17.5 / 142.5 / (92.2-210.3) / Female / 7 / 4.4 / 159.5 / (63.9-328.6)
Esophagus / Pancreas
Male / 4 / 3.1 / nc / (nc-nc) / Male / 7 / 3.8 / 184.1 / (73.7-379.3)
Female / 2 / 1.0 / nc / (nc-nc) / Female / 7 / 4.4 / 158.9 / (63.6-327.4)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.8 / nc / (nc-nc) / Male / 65 / 43.9 / 148.0 / (114.2-188.6)
Female / 0 / 0.7 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 8 / 5.7 / 140.9 / (60.7-277.6) / Male / 5 / 2.9 / 172.1 / (55.5-401.7)
Female / 4 / 3.7 / nc / (nc-nc) / Female / 3 / 2.0 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 1.8 / nc / (nc-nc) / Male / 1 / 1.2 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 6 / 4.1 / 148.1 / (54.1-322.5) / Male / 0 / 1.8 / nc / (nc-nc)
Female / 4 / 3.3 / nc / (nc-nc) / Female / 0 / 5.5 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 2.8 / nc / (nc-nc)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 11 / 9.3 / 118.5 / (59.1-212.1)
Lung and Bronchus / All Sites / Types
Male / 23 / 22.9 / 100.5 / (63.7-150.8) / Male / 189 / 158.3 / 119.4 / (103.0-137.7)
Female / 35 / 23.6 / 148.1 / (103.2-206.0) / Female / 163 / 156.1 / 104.4 / (89.0-121.7)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
13
Agawam
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 31 / 35.3 / 87.8 / (59.6-124.6) / Male / 19 / 21.6 / 88.0 / (53.0-137.4)
Female / 12 / 14.7 / 81.9 / (42.2-143.0) / Female / 14 / 18.2 / 77.1 / (42.1-129.3)
Brain and Other Nervous System / Multiple Myeloma
Male / 9 / 6.5 / 139.2 / (63.5-264.3) / Male / 3 / 5.5 / nc / (nc-nc)
Female / 10 / 5.6 / 177.8 / (85.1-327.1) / Female / 4 / 4.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 1.1 / nc / (nc-nc) / Male / 14 / 18.7 / 74.8 / (40.9-125.6)
Female / 149 / 130.1 / 114.5 / (96.9-134.5) / Female / 23 / 18.5 / 124.4 / (78.8-186.7)
Cervix Uteri / Oral Cavity & Pharynx
Male / 12 / 12.9 / 92.7 / (47.8-161.9)
Female / 1 / 5.1 / nc / (nc-nc) / Female / 4 / 6.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 48 / 46.8 / 102.5 / (75.6-135.9)
Female / 54 / 52.4 / 103.0 / (77.4-134.4) / Female / 17 / 13.5 / 125.9 / (73.3-201.6)
Esophagus / Pancreas
Male / 7 / 9.0 / 78.1 / (31.3-160.9) / Male / 12 / 10.7 / 112.0 / (57.8-195.7)
Female / 7 / 2.8 / 251.7 / (100.8-518.6) / Female / 12 / 12.9 / 93.2 / (48.1-162.8)
Hodgkin Lymphoma / Prostate
Male / 2 / 2.7 / nc / (nc-nc) / Male / 116 / 125.8 / 92.2 / (76.2-110.6)
Female / 5 / 2.2 / 231.0 / (74.5-539.2)
Kidney & Renal Pelvis / Stomach
Male / 18 / 16.7 / 107.5 / (63.7-170.0) / Male / 14 / 8.2 / 170.2 / (93.0-285.6)
Female / 13 / 10.9 / 119.1 / (63.4-203.7) / Female / 4 / 5.9 / nc / (nc-nc)
Larynx / Testis
Male / 7 / 5.3 / 131.9 / (52.8-271.7) / Male / 2 / 4.3 / nc / (nc-nc)
Female / 1 / 1.6 / nc / (nc-nc)
Leukemia / Thyroid
Male / 9 / 11.8 / 76.1 / (34.7-144.5) / Male / 5 / 5.8 / 86.8 / (28.0-202.5)
Female / 6 / 10.0 / 59.9 / (21.9-130.3) / Female / 19 / 18.6 / 102.4 / (61.6-159.9)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 6 / 8.4 / 71.6 / (26.2-155.9)
Female / 3 / 3.3 / nc / (nc-nc) / Female / 24 / 28.7 / 83.5 / (53.5-124.2)
Lung and Bronchus / All Sites / Types
Male / 61 / 63.1 / 96.7 / (74.0-124.2) / Male / 434 / 455.5 / 95.3 / (86.5-104.7)
Female / 74 / 67.6 / 109.4 / (85.9-137.3) / Female / 494 / 474.2 / 104.2 / (95.2-113.8)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
14
Alford
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 0 / 0.7 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc) / Female / 1 / 0.3 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 4 / 2.0 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 0 / 1.0 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.0 / nc / (nc-nc) / Male / 6 / 2.9 / 206.1 / (75.2-448.5)
Female / 0 / 0.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 0 / 1.3 / nc / (nc-nc) / Male / 12 / 9.7 / 124.2 / (64.1-217.0)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 8 / 6.7 / 119.2 / (51.3-234.8)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
15
Amesbury
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 13 / 16.0 / 81.4 / (43.3-139.2) / Male / 16 / 10.6 / 151.1 / (86.3-245.3)
Female / 6 / 6.3 / 95.0 / (34.7-206.8) / Female / 13 / 9.0 / 144.2 / (76.7-246.6)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 3.4 / nc / (nc-nc) / Male / 2 / 2.5 / nc / (nc-nc)
Female / 3 / 2.8 / nc / (nc-nc) / Female / 2 / 2.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.5 / nc / (nc-nc) / Male / 17 / 9.0 / 188.5 / (109.8-301.8)
Female / 54 / 62.8 / 85.9 / (64.6-112.1) / Female / 14 / 8.2 / 170.2 / (93.0-285.6)
Cervix Uteri / Oral Cavity & Pharynx
Male / 13 / 6.4 / 203.4 / (108.2-347.9)
Female / 4 / 2.8 / nc / (nc-nc) / Female / 7 / 3.1 / 224.3 / (89.9-462.2)
Colon / Rectum / Ovary
Male / 16 / 21.7 / 73.8 / (42.2-119.9)
Female / 20 / 22.3 / 89.7 / (54.7-138.5) / Female / 3 / 6.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 4 / 4.2 / nc / (nc-nc) / Male / 5 / 4.9 / 101.6 / (32.7-237.1)
Female / 0 / 1.2 / nc / (nc-nc) / Female / 7 / 5.5 / 127.9 / (51.3-263.6)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.5 / nc / (nc-nc) / Male / 60 / 60.4 / 99.3 / (75.8-127.8)
Female / 0 / 1.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 8.2 / 73.5 / (26.9-160.1) / Male / 2 / 3.8 / nc / (nc-nc)
Female / 4 / 5.1 / nc / (nc-nc) / Female / 2 / 2.5 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 2.5 / nc / (nc-nc) / Male / 3 / 2.6 / nc / (nc-nc)
Female / 0 / 0.7 / nc / (nc-nc)
Leukemia / Thyroid
Male / 5 / 5.7 / 87.6 / (28.2-204.4) / Male / 3 / 3.1 / nc / (nc-nc)
Female / 5 / 4.6 / 108.4 / (34.9-252.9) / Female / 3 / 10.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 4.1 / 123.2 / (39.7-287.6)
Female / 3 / 1.5 / nc / (nc-nc) / Female / 18 / 13.7 / 131.2 / (77.7-207.4)
Lung and Bronchus / All Sites / Types
Male / 35 / 29.2 / 119.7 / (83.4-166.5) / Male / 223 / 216.8 / 102.9 / (89.8-117.3)
Female / 31 / 30.0 / 103.2 / (70.1-146.4) / Female / 212 / 219.7 / 96.5 / (83.9-110.4)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
16
Amherst
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 9 / 17.7 / 50.8 / (23.2-96.4) / Male / 11 / 12.5 / 88.0 / (43.9-157.5)
Female / 10 / 7.3 / 137.2 / (65.7-252.4) / Female / 11 / 12.5 / 87.9 / (43.8-157.3)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 4.4 / nc / (nc-nc) / Male / 3 / 2.8 / nc / (nc-nc)
Female / 3 / 4.0 / nc / (nc-nc) / Female / 4 / 2.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.5 / nc / (nc-nc) / Male / 12 / 11.0 / 109.4 / (56.5-191.2)
Female / 92 / 72.0 / 127.8 / (103.0-156.7) / Female / 13 / 10.2 / 127.7 / (67.9-218.4)
Cervix Uteri / Oral Cavity & Pharynx
Male / 5 / 7.3 / 68.2 / (22.0-159.3)
Female / 3 / 3.5 / nc / (nc-nc) / Female / 4 / 3.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 17 / 24.0 / 70.9 / (41.3-113.6)
Female / 23 / 25.9 / 88.8 / (56.3-133.3) / Female / 7 / 8.0 / 87.1 / (34.9-179.4)
Esophagus / Pancreas
Male / 5 / 4.6 / 107.8 / (34.7-251.6) / Male / 7 / 5.4 / 128.4 / (51.5-264.7)
Female / 1 / 1.4 / nc / (nc-nc) / Female / 3 / 6.3 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 3.7 / nc / (nc-nc) / Male / 77 / 66.2 / 116.3 / (91.8-145.4)
Female / 1 / 3.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 11 / 8.9 / 123.6 / (61.6-221.2) / Male / 4 / 4.2 / nc / (nc-nc)
Female / 5 / 5.9 / 85.1 / (27.4-198.7) / Female / 2 / 2.9 / nc / (nc-nc)
Larynx / Testis
Male / 4 / 2.8 / nc / (nc-nc) / Male / 5 / 6.1 / 81.9 / (26.4-191.1)
Female / 2 / 0.9 / nc / (nc-nc)
Leukemia / Thyroid
Male / 7 / 7.5 / 93.1 / (37.3-191.9) / Male / 5 / 4.0 / 125.8 / (40.5-293.6)
Female / 1 / 5.9 / nc / (nc-nc) / Female / 10 / 15.3 / 65.5 / (31.4-120.5)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 4.5 / nc / (nc-nc)
Female / 2 / 1.7 / nc / (nc-nc) / Female / 16 / 16.1 / 99.3 / (56.7-161.3)
Lung and Bronchus / All Sites / Types
Male / 17 / 31.9 / 53.2 / (31.0-85.2) / Male / 216 / 250.1 / 86.4 / (75.2-98.7)
Female / 20 / 34.2 / 58.5 / (35.7-90.3) / Female / 244 / 265.4 / 91.9 / (80.8-104.2)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
17
Andover
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 32 / 33.6 / 95.3 / (65.2-134.5) / Male / 25 / 22.3 / 112.0 / (72.5-165.3)
Female / 10 / 12.9 / 77.7 / (37.2-142.9) / Female / 26 / 18.4 / 141.2 / (92.2-206.9)
Brain and Other Nervous System / Multiple Myeloma
Male / 11 / 7.0 / 156.2 / (77.9-279.4) / Male / 7 / 5.4 / 129.1 / (51.7-266.0)
Female / 5 / 5.7 / 87.2 / (28.1-203.4) / Female / 4 / 4.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 3 / 1.0 / nc / (nc-nc) / Male / 25 / 19.0 / 131.7 / (85.2-194.5)
Female / 117 / 133.6 / 87.6 / (72.4-105.0) / Female / 19 / 16.9 / 112.3 / (67.6-175.4)
Cervix Uteri / Oral Cavity & Pharynx
Male / 13 / 14.2 / 91.8 / (48.8-157.0)
Female / 2 / 5.6 / nc / (nc-nc) / Female / 0 / 6.5 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 38 / 46.2 / 82.2 / (58.1-112.8)
Female / 36 / 45.7 / 78.7 / (55.1-109.0) / Female / 13 / 13.3 / 97.8 / (52.0-167.2)
Esophagus / Pancreas
Male / 10 / 9.2 / 108.4 / (51.9-199.4) / Male / 13 / 10.5 / 123.5 / (65.7-211.2)
Female / 3 / 2.4 / nc / (nc-nc) / Female / 14 / 11.2 / 125.2 / (68.4-210.1)
Hodgkin Lymphoma / Prostate
Male / 3 / 2.9 / nc / (nc-nc) / Male / 179 / 132.5 / 135.1 / (116.1-156.4)
Female / 2 / 2.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 13 / 17.6 / 73.9 / (39.3-126.3) / Male / 9 / 7.9 / 113.6 / (51.9-215.7)
Female / 12 / 10.5 / 113.9 / (58.8-199.0) / Female / 3 / 5.0 / nc / (nc-nc)
Larynx / Testis
Male / 4 / 5.5 / nc / (nc-nc) / Male / 4 / 4.4 / nc / (nc-nc)
Female / 0 / 1.6 / nc / (nc-nc)
Leukemia / Thyroid
Male / 13 / 11.9 / 109.3 / (58.2-187.0) / Male / 7 / 6.4 / 109.1 / (43.7-224.9)
Female / 7 / 9.3 / 75.1 / (30.1-154.8) / Female / 30 / 20.7 / 144.7 / (97.6-206.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 8 / 9.0 / 88.8 / (38.2-175.0)
Female / 1 / 3.0 / nc / (nc-nc) / Female / 33 / 29.5 / 111.9 / (77.0-157.1)
Lung and Bronchus / All Sites / Types
Male / 40 / 62.2 / 64.3 / (45.9-87.6) / Male / 487 / 463.2 / 105.1 / (96.0-114.9)
Female / 43 / 61.9 / 69.5 / (50.3-93.6) / Female / 409 / 456.3 / 89.6 / (81.2-98.8)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
18
Aquinnah
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 1 / 0.3 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.0 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 1 / 1.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.1 / nc / (nc-nc)
Female / 1 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 0.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.0 / nc / (nc-nc) / Male / 3 / 1.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.0 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 0.5 / nc / (nc-nc) / Male / 8 / 4.0 / 200.1 / (86.2-394.3)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 3 / 4.0 / nc / (nc-nc)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
19
Arlington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 58 / 50.4 / 115.0 / (87.3-148.6) / Male / 33 / 30.9 / 106.8 / (73.5-150.0)
Female / 18 / 21.5 / 83.8 / (49.6-132.4) / Female / 31 / 27.4 / 113.3 / (77.0-160.9)
Brain and Other Nervous System / Multiple Myeloma
Male / 10 / 9.2 / 108.2 / (51.8-199.0) / Male / 5 / 7.7 / 64.6 / (20.8-150.8)
Female / 5 / 8.4 / 59.5 / (19.2-138.8) / Female / 8 / 6.8 / 118.4 / (51.0-233.3)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 1.5 / nc / (nc-nc) / Male / 24 / 26.5 / 90.6 / (58.0-134.7)
Female / 197 / 194.5 / 101.3 / (87.6-116.4) / Female / 20 / 27.1 / 73.8 / (45.0-113.9)
Cervix Uteri / Oral Cavity & Pharynx
Male / 13 / 18.0 / 72.2 / (38.4-123.5)
Female / 3 / 7.9 / nc / (nc-nc) / Female / 12 / 9.9 / 120.7 / (62.3-210.8)
Colon / Rectum / Ovary
Male / 63 / 66.1 / 95.3 / (73.2-122.0)
Female / 84 / 75.0 / 112.0 / (89.3-138.6) / Female / 19 / 20.0 / 95.1 / (57.3-148.6)
Esophagus / Pancreas
Male / 11 / 12.7 / 86.6 / (43.2-155.0) / Male / 17 / 15.2 / 111.9 / (65.2-179.2)
Female / 5 / 4.1 / 122.1 / (39.4-285.0) / Female / 21 / 18.7 / 112.6 / (69.7-172.1)
Hodgkin Lymphoma / Prostate
Male / 2 / 3.9 / nc / (nc-nc) / Male / 142 / 180.8 / 78.5 / (66.2-92.6)
Female / 5 / 3.3 / 153.0 / (49.3-357.0)
Kidney & Renal Pelvis / Stomach
Male / 26 / 23.8 / 109.2 / (71.3-160.0) / Male / 8 / 11.7 / 68.4 / (29.5-134.8)
Female / 11 / 16.4 / 67.0 / (33.4-119.9) / Female / 7 / 8.4 / 83.2 / (33.3-171.4)
Larynx / Testis
Male / 11 / 7.6 / 145.5 / (72.5-260.3) / Male / 10 / 6.7 / 149.2 / (71.4-274.4)
Female / 3 / 2.4 / nc / (nc-nc)
Leukemia / Thyroid
Male / 19 / 16.7 / 113.7 / (68.4-177.5) / Male / 14 / 8.4 / 167.2 / (91.3-280.5)
Female / 15 / 14.6 / 102.7 / (57.4-169.3) / Female / 33 / 29.0 / 113.6 / (78.2-159.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 11 / 11.7 / 94.1 / (46.9-168.4)
Female / 6 / 4.9 / 123.6 / (45.1-269.1) / Female / 40 / 43.0 / 93.1 / (66.5-126.8)
Lung and Bronchus / All Sites / Types
Male / 75 / 91.3 / 82.2 / (64.6-103.0) / Male / 608 / 651.0 / 93.4 / (86.1-101.1)
Female / 77 / 102.0 / 75.5 / (59.6-94.4) / Female / 679 / 703.3 / 96.5 / (89.4-104.1)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
20
Ashburnham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 4 / 4.9 / nc / (nc-nc) / Male / 2 / 3.6 / nc / (nc-nc)
Female / 0 / 1.6 / nc / (nc-nc) / Female / 4 / 2.8 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 1.2 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 1 / 0.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 2 / 3.0 / nc / (nc-nc)
Female / 15 / 19.4 / 77.3 / (43.2-127.4) / Female / 4 / 2.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 2.3 / nc / (nc-nc)
Female / 1 / 0.9 / nc / (nc-nc) / Female / 0 / 0.9 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 6 / 7.0 / 85.6 / (31.3-186.3)
Female / 8 / 5.6 / 143.1 / (61.6-282.0) / Female / 0 / 1.9 / nc / (nc-nc)
Esophagus / Pancreas
Male / 4 / 1.4 / nc / (nc-nc) / Male / 2 / 1.6 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 3 / 1.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.6 / nc / (nc-nc) / Male / 19 / 20.2 / 93.9 / (56.5-146.7)
Female / 0 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 4 / 2.8 / nc / (nc-nc) / Male / 1 / 1.2 / nc / (nc-nc)
Female / 0 / 1.4 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.9 / nc / (nc-nc) / Male / 4 / 0.9 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 1.9 / nc / (nc-nc) / Male / 0 / 1.1 / nc / (nc-nc)
Female / 1 / 1.3 / nc / (nc-nc) / Female / 5 / 3.5 / 141.9 / (45.7-331.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.5 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 6 / 4.2 / 144.5 / (52.8-314.5)
Lung and Bronchus / All Sites / Types
Male / 7 / 9.3 / 75.6 / (30.3-155.7) / Male / 63 / 71.5 / 88.2 / (67.7-112.8)
Female / 9 / 8.0 / 112.1 / (51.1-212.8) / Female / 71 / 62.9 / 112.8 / (88.1-142.3)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
21
Ashby
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 4 / 2.5 / nc / (nc-nc) / Male / 0 / 1.8 / nc / (nc-nc)
Female / 4 / 0.9 / nc / (nc-nc) / Female / 0 / 1.4 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 0.6 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 0 / 0.4 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 1 / 1.5 / nc / (nc-nc)
Female / 8 / 10.1 / 79.2 / (34.1-156.1) / Female / 4 / 1.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 1.2 / nc / (nc-nc)
Female / 1 / 0.5 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 8 / 3.5 / 226.2 / (97.4-445.7)
Female / 3 / 3.1 / nc / (nc-nc) / Female / 0 / 1.0 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.7 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 1 / 0.8 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.3 / nc / (nc-nc) / Male / 9 / 10.4 / 86.7 / (39.6-164.6)
Female / 0 / 0.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 1.4 / nc / (nc-nc) / Male / 0 / 0.6 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.9 / nc / (nc-nc) / Male / 0 / 0.6 / nc / (nc-nc)
Female / 1 / 0.7 / nc / (nc-nc) / Female / 1 / 1.7 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.7 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 4 / 2.2 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 5 / 4.8 / 105.0 / (33.8-245.0) / Male / 35 / 36.4 / 96.2 / (67.0-133.9)
Female / 1 / 4.4 / nc / (nc-nc) / Female / 31 / 33.5 / 92.4 / (62.8-131.2)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
22
Ashfield
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 1 / 2.2 / nc / (nc-nc) / Male / 1 / 1.4 / nc / (nc-nc)
Female / 2 / 0.7 / nc / (nc-nc) / Female / 3 / 1.1 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 0.4 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 2 / 1.2 / nc / (nc-nc)
Female / 10 / 7.8 / 128.0 / (61.3-235.5) / Female / 1 / 0.9 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.9 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 5 / 3.0 / 164.9 / (53.1-384.8)
Female / 2 / 2.3 / nc / (nc-nc) / Female / 0 / 0.8 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.6 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.2 / nc / (nc-nc) / Male / 8 / 8.2 / 97.2 / (41.8-191.5)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 1.1 / nc / (nc-nc) / Male / 1 / 0.5 / nc / (nc-nc)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 1 / 0.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.8 / nc / (nc-nc) / Male / 1 / 0.4 / nc / (nc-nc)
Female / 2 / 0.5 / nc / (nc-nc) / Female / 0 / 1.3 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.6 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 4 / 1.7 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 4 / 3.9 / nc / (nc-nc) / Male / 25 / 29.4 / 85.1 / (55.0-125.6)
Female / 1 / 3.3 / nc / (nc-nc) / Female / 27 / 25.2 / 107.0 / (70.5-155.7)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
23
Ashland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 20 / 13.8 / 145.3 / (88.7-224.5) / Male / 12 / 9.7 / 123.7 / (63.9-216.1)
Female / 4 / 4.8 / nc / (nc-nc) / Female / 7 / 8.0 / 87.5 / (35.0-180.3)
Brain and Other Nervous System / Multiple Myeloma
Male / 5 / 3.1 / 158.8 / (51.2-370.5) / Male / 5 / 2.2 / 222.2 / (71.6-518.6)
Female / 6 / 2.5 / 242.1 / (88.4-527.1) / Female / 1 / 1.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.4 / nc / (nc-nc) / Male / 7 / 8.1 / 86.1 / (34.5-177.4)
Female / 70 / 56.2 / 124.6 / (97.1-157.4) / Female / 12 / 6.5 / 183.8 / (94.8-321.0)
Cervix Uteri / Oral Cavity & Pharynx
Male / 6 / 6.0 / 100.0 / (36.5-217.7)
Female / 1 / 2.6 / nc / (nc-nc) / Female / 0 / 2.6 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 16 / 19.2 / 83.4 / (47.6-135.5)
Female / 17 / 16.5 / 103.3 / (60.1-165.4) / Female / 9 / 5.4 / 165.8 / (75.7-314.8)
Esophagus / Pancreas
Male / 1 / 3.9 / nc / (nc-nc) / Male / 6 / 4.3 / 138.3 / (50.5-301.1)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 6 / 4.0 / 148.2 / (54.1-322.5)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.4 / nc / (nc-nc) / Male / 68 / 55.1 / 123.5 / (95.9-156.5)
Female / 3 / 1.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 7.6 / 79.3 / (28.9-172.5) / Male / 4 / 3.3 / nc / (nc-nc)
Female / 2 / 4.3 / nc / (nc-nc) / Female / 1 / 1.8 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 2.3 / nc / (nc-nc) / Male / 3 / 2.5 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc)
Leukemia / Thyroid
Male / 7 / 5.0 / 139.0 / (55.7-286.4) / Male / 6 / 3.0 / 200.1 / (73.1-435.6)
Female / 3 / 3.7 / nc / (nc-nc) / Female / 13 / 10.0 / 130.2 / (69.2-222.6)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 5 / 3.8 / 131.7 / (42.4-307.3)
Female / 2 / 1.2 / nc / (nc-nc) / Female / 9 / 12.4 / 72.7 / (33.2-138.0)
Lung and Bronchus / All Sites / Types
Male / 17 / 26.0 / 65.5 / (38.1-104.9) / Male / 209 / 195.1 / 107.1 / (93.1-122.7)
Female / 28 / 24.3 / 115.3 / (76.6-166.7) / Female / 207 / 184.4 / 112.3 / (97.5-128.7)
Obs = observed case count; Exp = expected case count;